Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BOSTON SCIENTIFIC CORPORATION

(BSX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Boston Scientific : How Water Vapor Therapy Helped Charles Rezūm His Life

06/16/2021 | 12:18pm EDT

June 16, 2021

As an entrepreneur and small business owner, Charles Ellis developed a keen eye for identifying problems and opportunities solve them. However, when his need for frequent bathroom breaks due to benign prostate hyperplasia (BPH) started interfering with his daily life he wasn't immediately sure where to go for help.

More than 70% of men over the age of 70 are affected by BPH, also called benign prostate enlargement (BPE). Symptoms include frequent and urgent urination, difficulty urinating and incontinence.

Charles lived with his symptoms for more than a year before learning Rezūm™ Water Vapor Therapy, a minimally invasive treatment that uses water vapor to shrink the size of the prostate and alleviate BPH symptoms by reducing pressure on the bladder and urethra.

After researching treatment options and speaking with a clinical specialist, Charles decided to move forward with Rezūm Therapy. 'I'm quite happy with where I am at the moment,' he said. 'I don't worry about going to the loo when I arrive somewhere. In fact, sometimes I arrive places and I don't even think about it at all.'

To learn more about common symptoms of an enlarged prostate talk to your health care provider. For more information about Rezūm Water Vapor Therapy, please visit the following resources:

More information for individuals based in the United States is available here.

More information for individuals based in Europe is available here.

Safety information about Rezūm™ Water Vapor Therapy is available here.

Results from case studies are not necessarily predictive of results in other cases. Results in other cases may vary.

Disclaimer

Boston Scientific Corporation published this content on 16 June 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 June 2021 16:17:03 UTC.


ę Publicnow 2021
All news about BOSTON SCIENTIFIC CORPORATION
07/21BOSTON SCIENTIFIC : Late-Breaking Trial Data at TVT Demonstrate Sustained Safety..
PR
07/21Boston Scientific Corporation Announces Late-Breaking Trial Data at TVT Demon..
CI
07/19INSIDER TRENDS : Selling By Insiders Lingers at Boston Scientific
MT
07/16BOSTON SCIENTIFIC : How Choosing to Challenge Drove Her Path to Leadership
PU
07/13BOSTON SCIENTIFIC : What Makes Boston Scientific a Best Place to Work for Disabi..
PU
06/29BOSTON SCIENTIFIC : Announces Conference Call Discussing Second Quarter 2021 Res..
PR
06/25BOSTON SCIENTIFIC CORPORATION(NYSE : BSX) added to Russell 1000 Defensive Index
CI
06/25BOSTON SCIENTIFIC CORPORATION(NYSE : BSX) added to Russell 1000 Value-Defensive ..
CI
06/24BOSTON SCIENTIFIC CORP : Change in Directors or Principal Officers, Regulation F..
AQ
06/24Boston Scientific Corporation Appoints David S. Wichmann as Director
CI
More news
Financials (USD)
Sales 2021 11 758 M - -
Net income 2021 1 490 M - -
Net Debt 2021 6 054 M - -
P/E ratio 2021 44,1x
Yield 2021 -
Capitalization 62 691 M 62 691 M -
EV / Sales 2021 5,85x
EV / Sales 2022 5,24x
Nbr of Employees 38 000
Free-Float 84,2%
Chart BOSTON SCIENTIFIC CORPORATION
Duration : Period :
Boston Scientific Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BOSTON SCIENTIFIC CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 32
Last Close Price 44,12 $
Average target price 49,19 $
Spread / Average Target 11,5%
EPS Revisions
Managers and Directors
Michael F. Mahoney Chairman, President & Chief Executive Officer
Daniel J. Brennan Chief Financial Officer & Executive Vice President
Ian T. Meredith Global Chief Medical Officer & Executive VP
Jodi Eddy SVP, Chief Information & Digital Officer
Edward F. Mackey Executive Vice President-Global Operations
Sector and Competitors